(MedPage Today) — ORLANDO — Palopegteriparatide (Yorvipath) led to sustained improvements over 2 years in adults with chronic hypoparathyroidism, according to long-term phase III PaTHway trial results.
By week 104, nearly all participants…
Source link : https://www.medpagetoday.com/meetingcoverage/aace/115643
Author :
Publish date : 2025-05-18 23:20:00
Copyright for syndicated content belongs to the linked Source.
